Brief: Tiziana Life Sciences - Submits Request To FDA For Orphan Drug Designation For Intranasal Foralumab For Msa
30/09/2026 12:00
BRIEF-Tiziana Life Sciences - Submits Request To FDA For Orphan Drug Designation For Intranasal Foralumab For Msa Sept 30 (Reuters) - Tiziana Life Sciences Ltd TLSA.O:
TIZIANA LIFE SCIENCES - SUBMITS REQUEST TO FDA FOR ORPHAN DRUG DESIGNATION FOR INTRANASAL FORALUMAB FOR MSA
Source text: ID:nGNX6Vxk8m
Further company coverage: TLSA.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Tiziana Life Sciences
See all newsTiziana's experimental MS treatment meets main goals in mid-stage study
Brief: Tiziana Life Sciences - Submits Request To FDA For Orphan Drug Designation For Intranasal Foralumab For Msa
Brief: Tiziana Announces Last Patient Completes Last Visit In Phase 2A Inform-MS Trial Of Intranasal Foralumab
Brief: Tiziana Announces Last Patient Successfully Dosed In Its Phase 2 Inform-MS Trial
Brief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis